Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Carole Belaïdi |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months / Sidney H. Kennedy en European Neuropsychopharmacology, Año 2016 - Vol. 26 - No.2 (Febrero)
[artículo]
Título : Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months Tipo de documento: texto impreso Autores: Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor Fecha de publicación: 2021 Artículo en la página: pp. 378-389 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620
in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389[artículo] Sustained efficacy of agomelatine 10 mg, 25 mg, and 25–50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months [texto impreso] / Sidney H. Kennedy, Autor ; Alla S. Avedisova, Autor ; Carole Belaïdi, Autor . - 2021 . - pp. 378-389.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2016 - Vol. 26 - No.2 (Febrero) . - pp. 378-389
Palabras clave: Agomelatina, Depresión, Placebo, Régimen de dosis, Largo plazo Resumen: This randomized placebo-controlled “dose relation study” was conducted in patients who met criteria for major depressive disorder, to evaluate the efficacy and safety of agomelatine during 24 weeks at 3 doses (i) low fixed dosage (10 mg/day, n=100 patients entered the extension period),... Link: ./index.php?lvl=notice_display&id=26620